Literature DB >> 1975618

Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals.

W H Bakker1, E P Krenning, W A Breeman, J W Koper, P P Kooij, J C Reubi, J G Klijn, T J Visser, R Docter, S W Lamberts.   

Abstract

Radioiodinated Tyr-3-octreotide, a somatostatin analogue, is a useful ligand for the in vitro detection of somatostatin receptors. In this study, we have investigated the possible in vivo application of this radioligand in the detection of somatostatin receptor-bearing tumors by scintigraphy. The specific somatostatin-like biologic activity of radioiodinated Tyr-3-octreotide was confirmed in vitro: (a) radioiodinated Tyr-3-octreotide competes in the nanomolar range with specific receptor binding of somatostatin to suspended human meningioma membranes and (b) the secretion of growth hormone by cultured rat pituitary cells was similarly inhibited by iodinated Tyr-3-octreotide and somatostatin. In rats, intravenously injected 123I-Tyr-3-octreotide is rapidly cleared from the circulation mainly by the liver. Although this rapid clearance limits the amount of tracer available for somatostatin receptor-bearing tumors, the advantage of this rapid clearance is that the background level is rapidly reduced in favor of scintigraphic imaging of these tumors. Pancreatic tumors in rats were localized by scintigraphy after intravenous injection of 123I-Tyr-3-octreotide.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1975618

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  29 in total

1.  Investigation into the Biological Impact of Block Size on Cathepsin S-Degradable HPMA Copolymers.

Authors:  Wei Fan; Wenting Zhang; Yinnong Jia; Susan K Brusnahan; Jered C Garrison
Journal:  Mol Pharm       Date:  2017-03-21       Impact factor: 4.939

2.  Octreotide scintigraphy localizes somatostatin receptor-positive islet cell carcinomas.

Authors:  W Becker; J Marienhagen; R Scheubel; A Saptogino; W H Bakker; W A Breeman; F Wolf
Journal:  Eur J Nucl Med       Date:  1991

Review 3.  Where are we with nuclear medicine in pediatrics?

Authors:  H R Nadel
Journal:  Eur J Nucl Med       Date:  1995-12

4.  The scientific bases of cancer management: at the interface between fundamental research and clinical practice.

Authors:  M Tubiana
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

5.  Somatostatin analogue scintigraphy in carcinoid tumours.

Authors:  D J Kwekkeboom; E P Krenning; W H Bakker; H Y Oei; P P Kooij; S W Lamberts
Journal:  Eur J Nucl Med       Date:  1993-04

Review 6.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

Review 7.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

8.  Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors.

Authors:  C H van Eyck; H A Bruining; J C Reubi; W H Bakker; H Y Oei; E P Krenning; S W Lamberts
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

9.  Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.

Authors:  R Arnold; C Neuhaus; R Benning; W B Schwerk; M E Trautmann; K Joseph; C Bruns
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

10.  Radiolabeled octreotide. What lessons for antibody-mediated targeting?

Authors:  S J Mather; E Ur; J Bomanji; D Ellison; G M Besser; K E Britton
Journal:  Cell Biophys       Date:  1992 Aug-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.